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Abstract
Approximately 25–30% of patients with cancer undergo thoracic radiation therapy (RT). 
RT might inadvertently induce heart injury and result in various forms of radiation-
related heart disease (RRHD). The main endpoints of RRHD include cardiac death from 
RT, clinical heart disease (congestive heart disease, ischemic heart disease, and myocar-
dial infarction), and subclinical heart disease (cardiac perfusion defects). Advanced RT 
techniques, such as breath control, intensity-modulated RT, and image-guided RT, as well 
as limited target volume definition might spare or avoid cardiac doses and/or volume, 
which may translate into decreased incidence of RRHD. The total delivered radiation 
dose to cardiac implantable electronic devices was strongly recommended not to exceed 
2 Gy. The treatment strategies of RRHD were based on the various recommended con-
sensus of related heart diseases in cardiology. However, the standardized definitions of 
the cardiac structures, dose-volume limits during radiation planning design, the optimal 
dose-volume parameters, and the dose-volume effects of various cardiac substructures 
warrant further investigation. The recognition, prediction, prevention, and management 
of RRHD require close collaboration between oncologists and cardiologists.
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1. Introduction
Cancer is a leading cause of death in both developed and less developed countries world-
wide, and its health burden is expected to increase rapidly [1]. In 2012, an estimated 14.1 
million new cancer cases and 8.2 million deaths occurred worldwide [1]. Currently, approxi-
mately 57% of cancer cases and 65% of cancer deaths occur in less developed countries [1]. 
Worldwide, the new cases or deaths from lung and breast cancer were at the top of the list 
[1]. In China, in 2015, an estimated 4,292,000 new cancer cases and 2,814,000 cancer deaths 
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occurred [2]. Lung cancer is the most common incident cancer and the leading cause of cancer 
death in China, and esophageal cancer is also commonly diagnosed. Worldwide, lung, esoph-
ageal, and breast cancer account for approximately 27% of new cancer cases which means that 
more than 20% of patients will receive thoracic radiation therapy (RT). Many studies have 
proven that local RT improves local control and prolongs overall survival [3–11]. However, 
thoracic RT might inadvertently result in various forms of cardiac toxicity and manifest as 
clinical and subclinical cardiac disease, termed radiation-related heart disease (RRHD) [12, 
13]. In this chapter, we will present the epidemiological data and discuss the possible patho-
physiological mechanisms in brief. We will also address the cardiac avoidance techniques 
and the dose-volume-effect relationship. Although many cytotoxic and molecularly targeted 
drugs also result in various cardiac toxicities [14], consideration of these is outside the scope 
of this chapter.
2. Epidemiological data for radiation-related heart disease
Following the use of mantle field radiation for Hodgkin lymphoma in the 1960s, RRHD was 
recognized because substantial cardiac damage was observed to occur after the whole heart 
received doses of radiation higher than 30 Gy [12]. Traditionally, RRHD mainly included radia-
tion-related pericarditis, pericardial and myocardial fibrosis, and coronary artery disease, as well 
as conduction system abnormalities. However, with improvements in RT techniques and refine-
ments in RT delivery, radiation doses to the heart have decreased in the past three decades. For 
example, in lung and esophageal cancer, the mean heart dose might be >20 Gy [15], while in post-
operative RT for breast cancer, it might be <10 Gy [16, 17]. As a reference point, the survivors of 
the atomic bombings of Japan received up to 4 Gy [18]. The endpoints of RRHD could be catego-
rized as radiation-induced death from heart disease (mortality), clinical manifestations (clinical 
disease), and imaging or laboratory abnormalities (subclinical disease) [14] as shown in Figure 1.
Breast cancer is a curable disease. Therefore, minimization of anticancer therapy-induced tox-
icity is an important concern during treatment decision-making. In a study of breast cancer, 
mortality due to heart disease was increased by 27% (2p = 0.0001) in women who received 
surgery plus RT compared to the rate in those who did not receive postoperative RT. The 
proportional excess of vascular deaths was similar in the first decade and the period thereafter 
(ratio 1·32 vs. 1·27). However, the absolute rates were about three times higher in the second 
decade and the latter period for the patients with left-sided breast cancer [5]. Exposure to car-
diac radiation in the treatment of breast cancer will increase the subsequent rate of ischemic 
heart disease for more than 10 years after completion of the therapy. In addition, women with 
cardiac risk factors experience greater increases in risk after thoracic RT. Darby et al. quanti-
fied the dose effect of ischemic heart disease in patients with breast cancer who received 
adjuvant thoracic RT. They found that the rate of major coronary events increased by 7.4% 
per Gy without an apparent threshold, and the major coronary events included myocardial 
infarction, coronary revascularization, and death from ischemic heart disease [13, 19]. Even in 
the era of modern RT, in comparison with patients with right-sided breast cancer, those with 
left-sided breast cancer experienced a small increase in the risk of percutaneous coronary 
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intervention (PCI) following RT, and the 10-year cumulative incidences in patients with left-
sided and right-sided disease were 5.5 and 4.5%, respectively [20].
Hodgkin lymphoma usually occurs in young patients and is also one of the most curable can-
cers. Cytotoxic treatment with anthracyclines and vinca alkaloids and RT are the cornerstone 
choices for therapy of this cancer, and both are associated with the risk of cardiovascular 
disease. The cardiovascular risks after chemotherapy and RT have been well established [21, 
22]. According to data from old cohort studies, Hodgkin lymphoma was usually treated with 
radiation doses of 35–45 Gy using extended field treatment such as mantle field radiation. The 
cumulative risks of heart disease among survivors of adult Hodgkin lymphoma are approxi-
mately 5–10% at 15 years, 16% at 20 years, and 34% at 30 years, and coronary artery disease, as 
the most common form, accounts for approximately 40–50% of adverse cardiac events [23]. A 
recent systemic analysis showed that among 6039 patients with a median length of follow-up 
of 9 years, 703 patients were recorded to have 1238 first cardiovascular events, which mostly 
included ischemic heart disease (19%), congestive heart failure (12%), arrhythmia (16%), and 
valvular disease (11%). The predictors of cardiovascular disease were the mean heart radia-
tion dose per 1 Gy increase (HR 1015) and the dose of anthracyclines per 50 mg/m2 increase in 
cumulative dose (HR 1077) [24]. In a Dutch study conducted to examine the relative and abso-
lute excess risk of cardiovascular disease incidence, 1713 cardiovascular events were detected 
in 797 patients after a median follow-up of 20 years. Furthermore, 20% of patients with a 
cardiovascular disease developed multiple events. Mediastinal RT, anthracycline-containing 
chemotherapy, and smoking are appeared to be additive factors [25]. In addition, the data 
Figure 1. Radiation-related heart disease usually occurs with a certain latency from a few hours to several decades 
after the heart and its substructures receive direct or indirect irradiation. The endpoints of RRHD included its mortality 
and morbidity. According the occurrence timing of cardiac radiation response, RRHD includes acute and late cardiac 
toxicities. Generally, the probability of RRHD is positively related to the radiation dose that the heart received.
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from both individuals exposed to radiation during a medical career [26, 27] and survivors of 
the atomic bombings in Japan [28] proved that radiation was the source of the risk for RRHD.
Cardiac valvular disease is less common, typically has a late onset (10 years after RT), and is 
related to higher doses (30 Gy) or young age at treatment. Treatment of a large cardiac volume 
with high doses can produce acute pericarditis, although this is uncommon. At times, this 
may lead to chronic or delayed reemergence of pericarditis with effusion.
Furthermore, due to the wide use of advanced imaging techniques, more subclinical mani-
festations are detected. With repeat nuclear imaging to assess changes in regional and global 
cardiac function after RT for left-sided breast cancer, a prospective clinical study found that 
volume-dependent perfusion defects occurred in approximately 40% of patients within the 
first 2 years after RT for left-sided breast cancer, and these perfusion defects were associ-
ated with cardiac wall motion abnormalities [29]. In addition, new perfusion defects usually 
occurred in the anterior left ventricle within 6 months after radiation [30]. The data from the 
Surveillance, Epidemiology, and End Results Medicare database showed that patients with 
left-sided breast cancer who had a history of cardiac disease had an increased risk of PCI 
after thoracic RT, and there was a lower survival rate in those who received PCI. The 10-year 
cumulative PCI incidence was 5.5% [95% confidence interval (CI) 4.9–6.2%] and 4.5% (95% CI 
4.0–5.0%) for patients with left- and right-sided cancer, respectively [20].
For curable cancer types, such as breast cancer and Hodgkin lymphoma, both the radiation 
dose to the heart and its substructures and the risks and benefits of different regimens for 
individual patients should be well balanced during treatment decision-making.
3. Pathophysiological mechanisms of RRHD
The detailed pathogenesis of RRHD has been well reviewed [12, 31]. Overall, the endothelial 
system of blood vessels, particularly the arteries seem to be the critical target structures. After 
radiation, early functional alterations might include the pro-inflammatory responses and 
other changes, followed by slow progression [31, 32]. Although experimental animal models 
will help to elucidate the possible cellular and molecular mechanisms of RRHD, the results 
from various animals might be species-specific, and caution should be used in extrapolating 
to humans. In cancer patients, radiation induces macro- and microvascular injury. The former 
accelerates age-related atherosclerosis and leads to coronary artery disease after several years 
or decades due to reduced blood flow to the radiated myocardial territory. On the other hand, 
the latter reduces capillary density and results in decreased vascular reverse, which usually 
occurs within several months after RT and has only subclinical manifestations [12].
4. Dose-volume effect of RRHD
The dose-volume effect of RRHD is highly dependent on the definition of its endpoints. 
According to the length of its latency, RRHD could be divided into acute injury, which often 
manifests within a few months and is usually transient, and chronic toxicities, which often 
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manifest as congestive heart failure and ischemic heart disease, among others, and occur with 
a long latency [33]. RRHD can have subclinical manifestations, such as localized cardiac imag-
ing abnormalities on nuclear magnetic resonance imaging or regional wall motion abnor-
malities on cardiac ultrasonic examination, but manifestations could also be clinical, such as 
coronary artery disease or myocardial infarction [33].
The accurate definition of the heart and its substructures is critical to the estimation of the 
radiation dose-volume effect on RRHD. However, the imprecise definition of the heart in 
treatment planning computed tomography (CT) imaging poses a great challenge [33]. Feng 
et al. [34] developed a heart atlas to study cardiac exposure to radiation in the treatment of 
breast cancer. Using this consistent atlas for cardiac structure delineation, we could quantify 
the causative effects of RT on cardiac morbidity and mortality and study the dose-volume 
constraints on the heart and its substructures [34] (Figure 2).
Figure 2. Cardiac atlas is illustrated in the CT images with intravenous contrast [34] (with permission).
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In all of the published studies about the dose-volume response relationships of RRHD, mortal-
ity from pericarditis, ischemic heart disease, and decreased myocardial perfusion were three 
main clinical endpoints [33]. Gagliardi et al. [33] (Figure 3) summarized the dose-volume 
predictors and normal tissue complication probabilities of pericarditis/pericardial effusion, 
and the results showed that the mean doses to the pericardium (>30 Gy or >26.1 Gy) or medi-
astinum (>41 Gy) might be the predictors of radiation-induced pericarditis or pericardial effu-
sion. The incidence of pericarditis was 7% (14/198) with a radiation dose of ≤6 Gy; 12% (5/42) 
with a dose of 6–15 Gy; 19% (23/123) with a dose of 15–30 Gy; and 50% (7/14) with a dose of 
>30 Gy. Regarding cardiac mortality from ischemic heart disease or myocardial infarction, 
radiation dose to the mediastinum >30 Gy; 35% of heart volume receiving a radiation dose > 
38 Gy; mean dose to the whole heart volume > 2.5 Gy; and radiation to the internal mammary 
chain would be the predictive parameters [33]. When taking cardiac perfusion defects as the 
clinical endpoints, volume of the left ventricle receiving doses higher than 23 (V
23Gy
) or 33 Gy 
(V
33Gy
) could predict myocardial perfusion defects [35].
5. Cardiac dose sparing and avoidance techniques
For curable cancers, such as breast cancer and Hodgkin lymphoma, cardiac dose protection 
and/or avoidance techniques might be beneficial in minimizing RRHD. For breast cancer, sev-
eral techniques have been utilized clinically. These techniques include the following: (1) RT 
delivery with breath control or holding techniques, (2) prone patient positioning, (3) new RT 
techniques such as intensity-modulated RT (IMRT), proton therapy, or partial breast irradia-
tion techniques, and (4) single-fraction, intraoperative radiation [36] (Figure 4).
Figure 3. Dose-response curves of radiation-induced cardiac mortality. These data were estimated based on the breast 
cancer and Hodgkin lymphoma data sets [33] (with permission).
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With breath holding within inspiration, the distance from the chest wall to the heart will 
increase and the cardiac volume in the field will decrease, the mean or maximal dose to the 
heart or left anterior descending artery will be reduced [36], and the probability of cardiac 
mortality will also be reduced (4.8 vs. 0.1%) [37]. In the delivery of RT, patients are immobi-
lized in the prone position so that the breast falls away from the chest wall and the distance 
from the heart to the RT beam increases. A few studies showed that with this technique, 
75–85% of left-sided breast cancer patients had reduced cardiac volume in the field [38] and 
the mean cardiac dose decreased [39]. Although the main concerns of the prone position 
include its reproducibility and the potential increase in radiation to other normal tissues due 
to the poor setup, recent data showed that this technique could be well reproducible with 
daily cone-beam CT [40, 41].
For breast cancer patients, IMRT has been proven to have a cardiac dose sparing effect 
without compromising the dose homogeneity in the breast, especially for those with 
left-sided lesions [36, 42]. With the IMRT technique, the cardiac dose decreased with 
improved dose homogeneity in the breast [43]. A series of studies showed that, compared 
with breath holding in three-dimensional conformal RT and prone position techniques, 
IMRT has similar benefits and is more reproducible. The advantages of IMRT technique 
included the improvement of radiation dose homogeneity in target volume, the reduction 
of high cardiac dose volumes, and the decrease of normal tissue complication probability. 
In addition, IMRT technique showed its advantages in sparing the high-risk cardiac sub-
regions such as the anterior part of the heart, the coronary arteries, and the left ventricle 
[16, 17, 44].
Partial breast irradiation, as an alternative method to reduce the cardiac dose, could decrease 
the irradiated breast volume and increase the distance from the target volume to the heart. 
Hypofractionation is required by partial breast irradiation, and two recent reviews suggest 
that hypofractionation has not resulted in increased cardiac morbidity [45, 46]. Dosimetric 
studies showed that interstitial brachytherapy could reduce cardiac doses with image-
guided RT techniques [47, 48]. The mean cardiac dose decreased to 21% of the prescription 
dose in patients with left-sided breast cancer [48] and the cardiac volume receiving low 
doses (5 and 10 Gy) decreased significantly. In addition, the advantages of proton therapy 
including the rapid dose falloff and the Bragg peak make it possible to spare the radiation 
dose to the surrounding tissues including the heart. Several dosimetric studies showed that 
Figure 4. Cardiac sparing techniques is available nowadays. These techniques included radiation techniques improvement 
and patient or organ motion management.
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proton RT could reduce the maximal dose, V
20Gy
, V
5Gy
, etc [49–52]. However, because of the 
limited availability and high cost, at present, this technique is not advocated for cardiac dose 
sparing [36].
For Hodgkin lymphoma, the RT field has changed over the past decades. Previously, the 
majority of patients received mantle field radiation with/without upper abdomen field 
radiation, and a large volume of the heart had a prescribed dose irradiation. According to 
the anatomical sites of disease presence, the caudal border of the mantle field individually 
varied from the bottom border at the 8th–9th thoracic vertebrae (T8–T9) [53] to T10–T11 
[54, 55], and the higher caudal border might spare most of the irradiated heart volume 
[53]. With advanced imaging modalities such as positron emission tomography–CT and 
improved RT delivery techniques such as IMRT, image-guided RT, and breath control tech-
niques, among others, the previously applied extended field and involved field techniques 
have now been replaced by techniques using limited target volumes, such as involved 
node RT (INRT) and involved site RT (ISRT) [56]. With the optimal imaging during the 
course of treatment, both the INRT and ISRT techniques reduce the treated volume to a 
safe minimum [56]. In addition, with refinements of Hodgkin lymphoma, the prescription 
dose decreased to 20–36 Gy [57]. Due to more limited target volume and lower prescribed 
radiation doses, greater amounts of normal healthy tissues such as lung and heart could 
be spared.
Theoretically, for RT of non-small cell lung cancer, dose escalation to 74 Gy would be bet-
ter than the standardized 60 Gy dose. However, the results of a randomized phase 3 study 
(RTOG 0617) showed that a higher dose did not translate to a better outcome and might 
even be potentially harmful [58]. One reasonable explanation is that patients receiving doses 
of 74 Gy usually had worse dose-volume effects on the heart. The dose volume parameters 
including V
5Gy
 and V
30Gy
 of the heart were the important predictors of patient survival [58]. 
The dose-volume effects on the heart substructures such as the pericardium, atria, and ven-
tricles will be investigated and their dose-volume limitations will be included in future lung 
cancer trials. In addition, for early and locally advanced non-small cell lung cancer, proton RT 
will potentially be used for cardiac sparing [59].
6. Radiation for patients with cardiac implantable electronic devices
The numbers of patients with both cardiac implantable electronic devices (CIEDs) includ-
ing pacemakers (PMs) and implantable cardiac defibrillators and cancer are expected to rise, 
and patients in these situations require RT. The potential interactions between high doses of 
radiation and the function, longevity, and integrity of the CIEDs, as well as the harm to the 
patients, remain unclear. The results of a recent review [60, 61] showed that the risk of device 
failure increases with increasing radiation doses, without a clear cutoff point. For patients 
with pacemakers, the delivered total radiation dose to the device was strongly recommended 
not to exceed 2 Gy and the dose in patients with implantable cardiac defibrillators should be 
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within 1 Gy. The radiation energy should be less than 6 MV. Because of the potential dan-
gers of device malfunction, the radiation oncologist should have all the measures designed 
to minimize the risk to patients. Furthermore, it is necessary for the cardiologist, oncologist, 
radiotherapist, and physicist to collaborate closely.
7. Treatment strategies of RRHD
Generally, the treatment strategies of various RRHDs are similar to those in normal 
population [62–64]. For example, radiation-induced left ventricular dysfunction or heart 
failure could be treated according to the recommended guidelines of heart failure [65]. 
And for those with anticancer drug-induced hypertension, antihypertensive agents 
should be individualized to the clinical circumstances of the patients [66]. Angiotensin-
converting enzyme inhibitors or angiotensin II receptor blockers are usually considered 
for patients with proteinuria, metabolic syndrome, or high risk of chronic kidney disease 
[66]. Treatment with nondihydropyridine calcium channel blockers should be avoided in 
patients receiving cytochrome P450 inhibitors, while dihydropyridine calcium channel 
blockers are preferred in elderly patients [67, 68]. Low-molecular weight heparin for a 
minimum of 3–6 months is the recommended treatment for patients with newly diagnosed 
venous thromboembolism [69].
8. Unanswered questions regarding RRHD
Variability in certain risk factors may influence the development of a radiation-associated 
heart disease. These factors included patients themselves, RT techniques, the evaluable 
endpoints, and social-psychological variables [19]. The patient-related factors include age, 
personal alcohol and tobacco history, systemic anticancer drugs with potential cardiac 
toxicities such as anthracyclines, trastuzumab, taxanes, tamoxifen, and letrozole, among 
others, individual sensitivity to late heart morbidity, and hereditary heart disease [19]. 
The definitions of the heart and its substructures are shown in Table 1, and the standard-
ized delineation consensus and atlas should be consulted by radiation oncologists. For 
the heart and cardiac substructures, further investigation should be conducted regarding 
which dose-volume limitations were used during the design of radiation planning and 
what optimal dosimetric parameters were reported to be necessary, such as maximal or 
mean heart dose, V
5Gy
, V
10Gy
, V
20Gy
, etc. The clinical endpoints included cardiac mortal-
ity and radiation-associated clinical and subclinical heart diseases [33]. The optimal RT 
delivery techniques and reliable methods to evaluate these endpoints will require further 
studies. The designation of RRHD might unavoidably increase the psychological bur-
den of patients. In addition, to find those patients who may develop late RRHD, health 
economic evaluations should be critically performed prior to the initiation of screening 
programs [19].
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Substructure Definition Note
Heart [16, 34, 70] Cranial: The whole heart starts just 
inferior to the left pulmonary artery
Caudal: The heart blends with the 
diaphragm
If contrast is administered, the superior vena cava 
(SVC) can generally be separately contoured from 
the whole heart. In a noncontrast scan, the SVC can 
be included for simplification and consistency
Pericardium [34] The whole heart Cardiac vessels run in the fatty tissue within the 
pericardium and should be included in the contours
Left atrium [34] Begins just inferior to the left 
pulmonary artery
–
Left ventricle [16, 34] The visible heart according to both 
CT images and heart anatomy
Typically, anterior and to the left of the left atrium
Right atrium [34] No Starts to the right of the aortic root superiorly
Right ventricle [34] No Lies directly beneath the sternum and connects to 
the pulmonary trunk
Left main coronary 
artery [34, 70]
Defined from its origin in the aortic 
sinus to the first branches
Originates from the left side of the ascending aorta, 
inferior to the right pulmonary artery
Right coronary artery 
[34, 70]
Originates from the right side of the ascending aorta
Left anterior 
descending artery 
[34, 70]
Defined from where they branched at 
the left or right main coronary artery 
to the caudal edge of the endocardial 
surface of the left ventricle
Originates from the left coronary artery and runs in 
the interventricular groove between the right and 
left ventricles
Left circumflex artery 
[34, 70]
Originates from the left coronary artery and runs 
between the left atrium and ventricle
Right marginal artery 
[70]
–
Aortic valve [34] No Found within the ascending aorta and seen in cross 
section on axial CT
Pulmonic valve [34] No Found within the pulmonary trunk and seen in cross 
section on axial CT
Tricuspid valve [34] No Located between the right atrium and ventricle. It 
is difficult to see, but it is defined as the area where 
the blood pool between the atrium and ventricle is 
shared
Mitral valve [34] No Located between the left atrium and ventricle. It is 
difficult to see, but it is defined as the area where 
the blood pool between the atrium and ventricle is 
shared
Atrioventricular node 
[34]
No Cannot be seen on CT. It is located on the basal 
portion of the interventricular septum and extends 
between the right atrium and ventricle
Anterior myocardial 
territory [16, 17, 70]
Comprises the myocardium from 
the anterior surface of the heart up 
to 1.0 cm posteriorly and the main 
branches of the coronary arteries at 
the anterior portion of the heart
It is an imaged subregion in the anterior port of the 
heart as a high-risk region for breast cancer radiation 
therapy
Table 1. Recommended delineations of the heart and substructures.
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9. Conclusion
As a significant radiation-induced toxicity, RRHD should not be neglected during clini-
cal decision-making, especially for patients who could be cured by modern anticancer 
modalities. RRHD includes radiation-induced death from heart diseases, as well as clini-
cal and subclinical heart disease. Advanced RT techniques including breath control, IMRT, 
and imaging-guided RT might be used to avoid or spare cardiac doses and/or volume, 
which might translate into decreased incidence of RRHD. Furthermore, the significance 
and implications of RRHD differ depending on the clinical scenario; therefore, a consensus 
has not yet been reached regarding the recommended dose-volume limits. It is prudent to 
minimize the cardiac dose/volume and optimize the patient cardiovascular risk profiles. 
The recognition, prevention and prediction, and treatment of RRHD should be within the 
domain of oncocardiology, which requires close collaboration between oncologists and car-
diologists [14, 63].
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